Liposomal alendronate for the treatment of restenosis

The current treatment for coronary restenosis following balloon angioplasty involves the use of a mechanical or drug eluting stent (DES). The advent of DES systems has effectively allayed much of the challenge of restenosis that has plagued the success of percutaneous coronary interventions (PCI). H...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of controlled release 2012-07, Vol.161 (2), p.619-627
Hauptverfasser:	Gutman, Dikla, Golomb, Gershon
Format:	Artikel
Sprache:	eng
Schlagworte:	Alendronate - administration & dosage Alendronate - pharmacokinetics Alendronic acid Animals anti-inflammatory activity Balloons Bisphosphonate Bisphosphonates Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - pharmacokinetics Clinical trials Controlled release Coronary Restenosis - drug therapy Coronary Restenosis - immunology Drug delivery drugs Humans Immunity Implants Inflammation Injuries innate immunity Liposome Liposomes Macrophages Macrophages - drug effects Macrophages - immunology Monocytes Monocytes - drug effects Monocytes - immunology Monocytes/macrophages nanocarriers Pharmacokinetics Restenosis Thrombosis tissue repair Wound healing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!